# Structural Variant Disrupting the Expression of the Remote FOXC1 Gene in a Patient with Syndromic Complex Microphthalmia

Julie Plaisancié, Bertrand Chesneau, Lucas Fares-Taie, Jean-Michel Rozet, Jacmine Pechmeja, Julien Noero, Véronique Gaston, Isabelle Bailleul-Forestier, Patrick Calvas, Nicolas Chassaing

► To cite this version:

Julie Plaisancié, Bertrand Chesneau, Lucas Fares-Taie, Jean-Michel Rozet, Jacmine Pechmeja, et al. Structural Variant Disrupting the Expression of the Remote FOXC1 Gene in a Patient with Syndromic Complex Microphthalmia. International Journal of Molecular Sciences, 2024, 25 (5), pp.2669. 10.3390/ijms25052669. [hal-05534068](https://wwwHAL.fr/hal-05534068)

HAL Id: hal-05534068

https://ut3-toulouseinp.hal.science/hal-05534068v1

Submitted on 3 Mar 2026

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
<figure><img src="image_2.png" /></figure>

Case Report

# Structural Variant Disrupting the Expression of the Remote FOXC1 Gene in a Patient with Syndromic Complex Microphthalmia

Julie Plaisancié<sup>1,2,3,*</sup>, Bertrand Chesneau<sup>1,2,3 #</sup>, Lucas Fares-Taie<sup>4 #</sup>, Jean-Michel Rozet<sup>4 #</sup>, Jasmine Pechmeja<sup>2,5</sup>, Julien Noero<sup>1,3</sup>, Véronique Gaston<sup>1</sup>, Isabelle Bailleul-Forestier<sup>6</sup>, Patrick Calvas<sup>1,2</sup> and Nicolas Chassaing<sup>1,2,7</sup>

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Plaisancié, J.; Chesneau, B.; Fares-Taie, L.; Rozet, J.-M.; Pechmeja, J.; Noero, J.; Gaston, V.; Bailleul-Forestier, I.; Calvas, P.; Chassaing, N. Structural Variant Disrupting the Expression of the Remote FOXC1 Gene in a Patient with Syndromic Complex Microphthalmia. *Int. J. Mol. Sci.* **2024**, *25*, 2669. https://doi.org/10.3390/ijms25052669

Academic Editor: Alexander V. Ljubimov

Received: 17 January 2024

Revised: 21 February 2024

Accepted: 23 February 2024

Published: 25 February 2024

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2024 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

**Abstract:** Ocular malformations (OMs) arise from early defects during embryonic eye development. Despite the identification of over 100 genes linked to this heterogeneous group of disorders, the genetic cause remains unknown for half of the individuals following Whole-Exome Sequencing. Diagnosis procedures are further hampered by the difficulty of studying samples from clinically relevant tissue, which is one of the main obstacles in OMs. Whole-Genome Sequencing (WGS) to screen for non-coding regions and structural variants may unveil new diagnoses for OM individuals. In this study, we report a patient exhibiting a syndromic OM with a de novo 3.15 Mb inversion in the 6p25 region identified by WGS. This balanced structural variant was located 100 kb away from the *FOXC1* gene, previously associated with ocular defects in the literature. We hypothesized that the inversion disrupts the topologically associating domain of *FOXC1* and impairs the expression of the gene. Using a new type of samples to study transcripts, we were able to show that the patient presented monoallelic expression of *FOXC1* in conjunctival cells, consistent with the abolition of the expression of the inverted allele. This report underscores the importance of investigating structural variants, even in non-coding regions, in individuals affected by ocular malformations.

**Keywords:** structural variant; inversion; FOXC1; Axenfeld-Rieger; microphthalmia; eye malformation

**1. Introduction**

Ocular malformations (OMs) constitute a group of clinically and genetically heteroge-
nous disorders, representing the visible outcome of early defects during eye development.
This rare group of disorders represents around 1/3000 newborns [1]. They mainly manifest
as ocular growth defects (microphthalmia and anophthalmia, respectively, reduced eye
size or absent eye), coloboma (closure defect of the optic fissure), aniridia and anterior
segment dysgeneses (ASD). These ocular anomalies can affect one or two eyes and can
also be associated with each other. When associated with a structural anomaly of the eye,
microphthalmia is called complex microphthalmia. A hundred genes have been implicated

<footnote n="1">¹ Laboratoire de Référence des Anomalies Malformatives de l'Œil, Institut Fédératif de Biologie, Centre Hospitalier Universitaire de Toulouse, 31300 Toulouse, France; chesneau.b@chu-toulouse.fr (B.C.); calvas.p@outlook.fr (P.C.)</footnote>

<footnote n="2">² Centre de Référence des Affections Rares en Génétique Ophtalmologique (CARGO), Centre Hospitalier Universitaire de Toulouse, 31300 Toulouse, France</footnote>

<footnote n="3">³ Molecular, Cellular and Developmental Biology Unit (MCD), Centre de Biologie Intégrative (CBI), (CNRS), Université Toulouse III Paul Sabatier (UPS), Université de Toulouse, 31062 Toulouse, France</footnote>

<footnote n="4">⁴ Laboratoire de Génétique Ophtalmologique, Institut national de la Santé et de la Recherche Médicale (INSERM) U1163, Institut Imagine, 75015 Paris, France; lucas.fares-taie@inserm.fr (L.F.-T.)</footnote>

<footnote n="5">5 Service d'Ophtalmologie, Hôpital Purpan, Centre Hospitalier Universitaire de Toulouse, 31300 Toulouse, France</footnote>

<footnote n="6">6 Competence Centre of Oral Diseases, Centre Hospitalier Universitaire de Toulouse, 31300 Toulouse, France; isabelle.bailleul-forestier@univ-tlse3.fr</footnote>

<footnote n="7">7 Laboratoire AURAGEN, 69003 Lyon, France</footnote>

<footnote>* Correspondence: plaisancie.j@chu-toulouse.fr</footnote>
in this wide and overlapping ocular phenotypic spectrum [2]. Taking all these OMs to-
gether, the genetic diagnostic yield does not exceed 50% even when using Whole-Exome
Sequencing (WES) and many patients remain genetically undiagnosed [2–4].

Indeed, the number of OM individuals lacking a genetic diagnosis stays largely
unchanged after the analysis of the main known genes by Targeted- or Whole-Exome
Sequencing. The identification of new genes in OMs is actually rare, typically occurring
within isolated families [5]. In other words, it seems possible that most of the main
genes involved in OMs have already been discovered and that the mechanisms or lesions
responsible, in particular those affecting the expression regulation of these genes, remain
to be identified. Whole-Genome Sequencing (WGS) therefore appears as an interesting
approach in patients with a negative WES because it allows the exploration of non-coding
regions as well as the detection of balanced or unbalanced structural variants (SVs) both in
coding and non-coding regions [6]. Access of non-coding regions by WGS allows detecting
non-coding variants that can affect the expression of known genes. For example, Bhatia
S, 2013 [7] showed the impact of a single nucleotide variant (SNV) in a 150 kb distant
cis-regulatory element on the *PAX6* gene expression. Moreover, Hall et al. [8] recently
demonstrated the contribution of WGS in a cohort of patients with aniridia without a
genetic diagnosis, with the identification of SNVs as well as SVs affecting the *PAX6* locus.
The easier accessibility of WGS in routine procedures will facilitate the exploration and
the understanding of the non-coding part of genomes. This is why dissecting the impact
of non-coding variants on gene expression is crucial to advancing knowledge on genome
structure and function.

Here, we report a patient displaying a syndromic OM in whom we identified by WGS a 3.15 Mb inversion in the 6p25 region. This SV was located 100 kb 3' to the *FOXC1* gene. This gene is well known for its involvement in syndromic ocular defects, notably Rieger syndrome [9]. Thus, we hypothesized that the balanced SV disrupts the topologically-associating domain (TAD) where the *FOXC1* gene is contained and therefore impacts the expression of this latter. This report underlines the need to look for SVs in coding and non-coding regions of genes involved in ocular development in order to increase the yield of genetic diagnoses in patients.

**2. Results**

**2.1. *Clinical Data***

The patient has no particular familial medical history, except for a marfanoid habitus (mild skeletal features, mitral prolapse) observed in his mother, which did not meet the diagnostic criteria for Marfan syndrome [10]. The pregnancy and delivery were uneventful. At 3 months old, ophthalmological examination revealed bilateral sclerocornea with left mild microphthalmia. Ocular examination under general anesthesia ruled out lens, retinal or optic nerve anomalies. A right penetrating keratoplasty was performed, but the corneal graft progressively opacified, leading to phthisis. Consequently, a right ocular prosthesis was implanted at the age of 12.

Additionally, the patient exhibited mild neurodevelopmental delay and autistic fea-
tures (mainly stereotypies), with normal neurological examination. Hearing was within
normal limits. Brain MRI identified bitemporal arachnoids cysts and cysts of the lucidum
septum (Figure S1). He is now a 13-year-old boy schooled half in an ordinary environment
and half in a sheltered structure adapted for the visually impaired.

During the clinical examination, craniofacial features were observed, including small
dysplastic ears, hypertelorism and turricephaly (Figure 1). Dental anomalies comprised
areas of hypomineralization, yellowish tendency teeth and chromogenic bacterial flora,
although the number of tooth germs was normal. Skeletal features encompassed a slender
build, bilateral elbow deformation with decreased mobility and pes planus.
<figure><img src="image_5.png" /><figcaption>**Figure 1.** Pictures of the proband. (a) Craniofacial features with corneal opacity of the left eye, prosthetic right eye, hypertelorism and enamel anomalies. (b) Skeletal features with slender build and bilateral elbow deformation.</figcaption></figure>

## 2.2. Genetic Data

The WGS analysis highlighted a de novo inversion of 3.15 Mb: seq[GRCh38]inv(6)-(p25.1p25.3)dn;NC:g.1713354_4870965inv (Figure 2a). Breakpoints were located in two genes: *GMDS* (chr6:1713354, within intron 9) and *CDYL* (chr6:4870965, within intron 3). Remarkably, the inversion was located 100 kb 3' of the *FOXC1* gene (Figure 2b), already known in syndromic OM [11].

Using POSTRE, we were able to provide mechanistic putative insights of the inversion: a *GMDS* "loss-of-function" and a remote effect on the *FOXC1* gene expression. No effect was predicted regarding the second breakpoint (Figure S2).

Given the OM and the unusual dental phenotype exhibited by the patient, the disruption of *FOXC1* expression seemed to be the most clinically plausible causative mechanism. To demonstrate the impact of this inversion, we used a differentially expressed alleles approach. We were able to take a sample of a clinically relevant tissue (conjunctival cells) from him and demonstrate sufficient expression of *FOXC1* to allow transcript analysis. We knew from WGS that the proband had two heterozygous benign SNVs in the *FOXC1* coding sequence (NM_001453.3:c.[1139_1141dup;1359_1361dup];[=]) both inherited from the father, thus allowing distinction with the maternal inherited allele. The study of *FOXC1* transcripts showed the abolition of the paternal allele expression (Figure 2d) and confirms our hypothesis of the involvement of this inversion downstream of *FOXC1* in the patient's phenotype.
<figure><img src="image_6.png" /></figure>

<table><caption>**Figure 2.** (a) Visualization of aligned genomic data obtained from the proband and his parents (IGV viewer) showing (in the proband only) two breakpoints (BP1 and BP2) and abnormally paired mates with higher distance and same orientation (in blue), revealing a de novo inversion of 3.15 Mb in the 6p25 region. (b) From Genome Browser database of the University of California, Santa Cruz (UCSC) [http://genome.ucsc.edu](http://genome.ucsc.edu), URL accessed on 16 January 2024), we can see that the inversion (black rectangle) breakpoints do not disrupt any gene previously associated with a phenotype (OMIM database, green rectangles). However, BP1 disrupts *GMDS* and BP2 disrupts *CDYL* transcripts (blue line and bars). Moreover, BP1 is located 100 kb 3' to the *FOXC1* transcript. Underneath are presented remapped interactions between enhancers and promoters, data from d'Aurizio et al., 2022 [12] and heatmaps of chromatin folding data from Micro-C XL experiments on the H1-hESC (embryonic stem cells). (c) Impact (predicted by POSTRE) of the inversion moving away the cis-regulatory elements from the *FOXC1* gene that they control. (d) We can see on the electropherograms that the patient is indeed a carrier of two heterozygous variants of the *FOXC1* gene after amplification and Sanger sequencing of two different fragments of the gene from genomic DNA (SG101293). Then, when we analyze the transcripts of this gene on RNA conjunctival sample (EYE230001), we can observe the absence of the two *FOXC1* variants and, therefore, the paternal allele carrying these two variants. Unhighlighted lines correspond to the reference sequence, the dark blue highlighted line corresponds to the reference protein sequence, blue and red bars represent PHRED quality scores of base calling (blue indicating quality > 30, red indicating quality < 20), and the blue and red highlighted line represents the sequence found in the patient, colors of the electropherogram represent the four nucleobases (cytosine (blue), guanine (black), thymine (red) and adenine (green)).</caption><thead><tr><th></th><th>FRAGMENT 1 (c.1139_1141dup)</th><th>FRAGMENT 2 (c.1359_1361dup)</th></tr></thead><tbody><tr><td>SG101293<br>PCR FOXC1</td><td></td><td></td></tr><tr><td>EYE230001<br>RT-PCR<br>FOXC1</td><td></td><td></td></tr></tbody></table>
### 3. Discussion

In this study, we have demonstrated, for the first time, that an inversion located far from an ocular developmental gene can disrupt its expression, leading to an OM in the patient. Indeed, *FOXC1* is involved in phenotypes associated with OMs (mainly anterior segment dysgenesis and microphthalmia) and extraocular lesions [11]. This gene encodes a transcription factor with a forkhead domain that binds DNA [9]. While the Axenfeld-Rieger anomaly (OMIM#602482) is the characteristic ASD linked to *FOXC1* mutations, the existing literature has associated various ocular defects, including microphthalmia, with pathogenic variants in this gene [9,13,14]. Moreover, some of the extra-ocular features observed in our patient such as brain abnormalities align with those recently listed as associated with *FOXC1* mutations [11]. Given the correlation between the observed phenotype and the loss of expression of a *FOXC1* allele, we concluded that the inversion was the causative genetic event behind the observed phenotype in our patient.

The overall phenotype exhibited by the individual described here closely resembles the Rieger-like phenotype observed in individuals with 6p25 deletions encompassing *FOXC1* [15,16]. In both instances, affected individuals exhibit craniofacial features characterized hypertelorism, skeletal anomalies and neuro-developmental delay. This underscores the implication of *FOXC1* as a major gene of 6p25 deletion. The implication of the two genes disrupted at the breakpoints (*GMDS* and *CDYL*) is, however, difficult to demonstrate. Despite their inclusion in Online Mendelian Inheritance in Man (OMIM, https://www.omim.org/, URL accessed on 16 January 2024), these two genes have not been previously associated with Mendelian disorders. *GMDS* encodes for GDP-mannose 4,6-dehydratase, an enzyme involved in GDP-fucose synthesis [17]. *CDYL* encodes for CDY-like protein, which seems to play a role, but which is largely unknown, in epigenetic regulation [18]. Their expression is rather ubiquitous in humans (not specific to the eye). No OM was reported in animal models (Alliance of Genome Resource V.6.0.0, https://www.alliancegenome.org/, URL accessed on 16 January 2024) and no implication in eye development was described in the literature for either of these genes. Their pLI (*GMDS* = 0.99, *CDYL* = 1) and LOEUF scores (*GMDS* = 0.09, *CDYL* = 0.05) support a high intolerance to loss-of-function variants [19]. Regarding *GMDS*, only one c.740G>C variant (p.Arg247Pro) of unknown signification is listed in the Human Gene Mutation Database (http://www.hgmd.org, URL accessed on 5 December 2023) due to its unique occurrence in a patient in a large cohort of nearly 9000 patients with neurodevelopmental disorders [20]. For *CDYL*, no variants were listed in the HGMD database.

The disruption of *FOXC1* expression is likely a consequence of the inversion interfering with a TAD in which the gene is expressed during ocular development (Figure 2b,c). The in silico analysis using POSTRE indeed indicates that the inversion leads to the loss of 11 of the 13 enhancers present on the regulatory domain of *FOXC1* and a reduction of almost 70% of the total level of H3K27ac marks reported to the number of these enhancers (which reflects the regulatory activity of these enhancers) in early neural crest cells (Supplementary Data). Furthermore, a recent study by D'Aurizio et al. [12] has remapped enhancer-promoter long-range interactions identified in mouse neural stem cells onto the human genome. This work revealed that one of these interactions links an enhancer located within the inverted region (wTR1_1881) to the promoter of *FOXC1* (Figure 2b).

It is crucial to highlight that transcript analysis was feasible due to the expression of *FOXC1* in a readily accessible tissue, which is not commonly the case for many OM genes. Furthermore, the presence of heterozygous *FOXC1* variants in the proband significantly facilitated the study, enabling the examination of the differential expression of the two alleles.

This study underscores the significance of employing a WGS approach for OM individuals who previously yielded negative results with WES. The identification of SVs impacting the regulation of the expression of distant ocular genes, despite their intact coding sequences, appears to represent a novel category of variants warranting careful exploration. Limited data exist in the literature regarding the impact of a WGS strategy
in OMs. The few published studies indicate a modest diagnosis impact of, respectively, 24% [5] and 15% [21] in two cohorts of patients with micro-anophthalmia, though SVs were not investigated. Notably, two cases of aniridia were resolved by detecting cryptic SVs in the *PAX6* locus by using long-read WGS [22].

This finding supports our working hypothesis that a significant number of individuals with OM might present variants affecting the transcriptional control of known ocular genes, but with molecular mechanisms making it difficult to identify.

Beyond direct medical applications for patients, such sequencing strategies hold the promise of advancing our comprehension of the transcriptional networks and regulatory mechanisms operative in ocular development. This has both scientific and potentially therapeutic significance, particularly when using approaches aimed at restoring the expression of the gene whose sequence is otherwise intact.

# 4. Materials and Methods

## 4.1. *Clinical Evaluation*

This study was designed in compliance with the Declaration of Helsinki and informed consent was obtained from the patient and his parents. Full medical and familial history was collected. Patient underwent detailed general and ophthalmological examination. Brain MRI was performed to investigate the visual tract and intracerebral structures. Array-comparative genomic hybridization (array-CGH) and WES did not detect any variant of interest.

## 4.2. *Genetic Analytes*

WGS was carried out within the AURAGEN sequencing platform in France. Blood genomic DNA was used to prepare the WGS library, using the Illumina TruSeq DNA PCR-Free Library Preparation Kit, according to the manufacturer's instructions. The libraries were sequenced on a NovaSeq 6000 (Illumina, San Diego, CA, USA), as paired-end 150 bp reads, to target a minimal average sequencing depth of 20×. After demultiplexing (bcl2fastq, Illumina), sequences were aligned to the human genome GRCh38.p13 using the BWA-MEM (0.7.17). SNV calls were made with the GATK Haplotypecaller v.4. The Large Variant calls (CNV and SV) were made by combining Manta (1.6.0) and CNVnator (0.4.1). Both parental samples were shown to be the biological parents of the patient using SNVs on WGS data. Annotation was conducted with Variant Effect Predictor (v.98.3) and further filtering was performed using an in-house pipeline.

SV breakpoints were confirmed by Sanger sequencing of genomic DNA extracted from a second blood sample. The SV effects were studied using the in silico tool named POSTRE (v1.0.0) for Prediction Of STRuctural variant Effects [23]. The *FOXC1* mRNA expression was studied by RT-PCR after RNA extraction (Qiagen, Hilden, Germany) performed on conjunctival cells (EYEPRIM, Opia Technologies, Paris, France).

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms25052669/s1.

**Author Contributions:** All authors have revised the manuscript. J.P. (Julie Plaisancié) wrote the first draft. J.P. (Julie Plaisancié), J.P. (Jacmine Pechmeja), I.B.-F. and P.C. collected the clinical data. J.P. (Julie Plaisancié), B.C., L.F.-T., J.-M.R., J.N., V.G. and N.C. collected, performed and analyzed the different biological analyses. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** We describe here a case report of an individual followed at Toulouse University Hospital. All the data were collected during usual clinical care and no additional exam was performed for this study. The ethical board of Toulouse University Hospital have therefore exempted this study from ethical approval.

**Informed Consent Statement:** Written informed consent has been obtained from the patient's legal guardians to publish this paper.
**Data Availability Statement:** All clinical and biological data relevant for the study are described in the main text and Supplementary Materials. The novel structural variant was reported in ClinVar database (SCV004042673).

**Acknowledgments:** This research was made possible through access to the data generated by the France Genomic Medicine Plan 2025.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Bermejo, E.; Martínez-Frías, M.L. Congenital Eye Malformations: Clinical-Epidemiological Analysis of 1,124,654 Consecutive Births in Spain. *Am. J. Med. Genet.* **1998**, *75*, 497–504. [CrossRef]

2. Plaisancié, J.; Ceroni, F.; Holt, R.; Zazo Seco, C.; Calvas, P.; Chassaing, N.; Ragge, N.K. Genetics of Anophthalmia and Microphthalmia. Part 1: Non-Syndromic Anophthalmia/Microphthalmia. *Hum. Genet.* **2019**, *138*, 799–830. [CrossRef]

3. Patel, N.; Khan, A.O.; Alsahli, S.; Abdel-Salam, G.; Nowilaty, S.R.; Mansour, A.M.; Nabil, A.; Al-Owain, M.; Sogati, S.; Salih, M.A.; et al. Genetic Investigation of 93 Families with Microphthalmia or Posterior Microphthalmos. *Clin. Genet.* **2018**, *93*, 1210–1222. [CrossRef]

4. Haug, P.; Koller, S.; Maggi, J.; Lang, E.; Feil, S.; Wlodarczyk, A.; Bähr, L.; Steindl, K.; Rohrbach, M.; Gerth-Kahlert, C.; et al. Whole Exome Sequencing in Coloboma/Microphthalmia: Identification of Novel and Recurrent Variants in Seven Genes. *Genes* **2021**, *12*, 65. [CrossRef] [PubMed]

5. Harding, P.; Gore, S.; Malka, S.; Rajkumar, J.; Oluonye, N.; Moosajee, M. Real-World Clinical and Molecular Management of 50 Prospective Patients with Microphthalmia, Anophthalmia and/or Ocular Coloboma. *Br. J. Ophthalmol.* **2023**, *107*, 1925–1935. [CrossRef]

6. Liu, X.; Hu, F.; Zhang, D.; Li, Z.; He, J.; Zhang, S.; Wang, Z.; Zhao, Y.; Wu, J.; Liu, C.; et al. Whole Genome Sequencing Enables New Genetic Diagnosis for Inherited Retinal Diseases by Identifying Pathogenic Variants. *NPJ Genom. Med.* **2024**, *9*, 6. [CrossRef] [PubMed]

7. Bhatia, S.; Bengani, H.; Fish, M.; Brown, A.; Divizia, M.T.; de Marco, R.; Damante, G.; Grainger, R.; van Heyningen, V.; Kleinjan, D.A. Disruption of Autoregulatory Feedback by a Mutation in a Remote, Ultraconserved PAX6 Enhancer Causes Aniridia. *Am. J. Hum. Genet.* **2013**, *93*, 1126–1134. [CrossRef] [PubMed]

8. Hall, H.N.; Parry, D.; Halachev, M.; Williamson, K.A.; Donnelly, K.; Campos Parada, J.; Bhatia, S.; Joseph, J.; Holden, S.; Prescott, T.E.; et al. Short-Read Whole Genome Sequencing Identifies Causative Variants in Most Individuals with Previously Unexplained Aniridia. *J. Med. Genet.* **2024**, *61*, 250–261. [CrossRef]

9. Kaur, K.; Ragge, N.K.; Ragoussis, J. Molecular Analysis of FOXC1 in Subjects Presenting with Severe Developmental Eye Anomalies. *Mol. Vis.* **2009**, *15*, 1366–1373.

10. Loeys, B.L.; Dietz, H.C.; Braverman, A.C.; Callewaert, B.L.; De Backer, J.; Devereux, R.B.; Hilhorst-Hofstee, Y.; Jondeau, G.; Faivre, L.; Milewicz, D.M.; et al. The Revised Ghent Nosology for the Marfan Syndrome. *J. Med. Genet.* **2010**, *47*, 476–485. [CrossRef]

11. Reis, L.M.; Maheshwari, M.; Capasso, J.; Atilla, H.; Dudakova, L.; Thompson, S.; Zitano, L.; Lay-Son, G.; Lowry, R.B.; Black, J.; et al. Axenfeld-Rieger Syndrome: More than Meets the Eye. *J. Med. Genet.* **2023**, *60*, 368–379. [CrossRef]

12. D'Aurizio, R.; Catona, O.; Pitasi, M.; Li, Y.E.; Ren, B.; Nicolis, S.K. Bridging between Mouse and Human Enhancer-Promoter Long-Range Interactions in Neural Stem Cells, to Understand Enhancer Function in Neurodevelopmental Disease. *Int. J. Mol. Sci.* **2022**, *23*, 7964. [CrossRef]

13. Gould, D.B.; Smith, R.S.; John, S.W.M. Anterior Segment Development Relevant to Glaucoma. *Int. J. Dev. Biol.* **2004**, *48*, 1015–1029. [CrossRef]

14. Reis, L.M.; Tyler, R.C.; Weh, E.; Hendee, K.E.; Schilter, K.F.; Phillips, J.A.; Sequeira, S.; Schinzel, A.; Semina, E.V. Whole Exome Sequencing Identifies Multiple Diagnoses in Congenital Glaucoma with Systemic Anomalies: WES in Congenital Glaucoma with Systemic Anomalies. *Clin. Genet.* **2016**, *90*, 378–382. [CrossRef]

15. De Vos, I.J.H.M.; Stegmann, A.P.A.; Webers, C.A.B.; Stumpel, C.T.R.M. The 6p25 Deletion Syndrome: An Update on a Rare Neurocristopathy. *Ophthalmic Genet.* **2017**, *38*, 101–107. [CrossRef] [PubMed]

16. Aldinger, K.A.; Lehmann, O.J.; Hudgins, L.; Chizhikov, V.V.; Bassuk, A.G.; Ades, L.C.; Krantz, I.D.; Dobyns, W.B.; Millen, K.J. FOXC1 Is Required for Normal Cerebellar Development and Is a Major Contributor to Chromosome 6p25.3 Dandy-Walker Malformation. *Nat. Genet.* **2009**, *41*, 1037–1042. [CrossRef] [PubMed]

17. Ohyama, C.; Smith, P.L.; Angata, K.; Fukuda, M.N.; Lowe, J.B.; Fukuda, M. Molecular Cloning and Expression of GDP-D-Mannose-4,6-Dehydratase, a Key Enzyme for Fucose Metabolism Defective in Lec13 Cells. *J. Biol. Chem.* **1998**, *273*, 14582–14587. [CrossRef]

18. Fischle, W.; Franz, H.; Jacobs, S.A.; Allis, C.D.; Khorasanizadeh, S. Specificity of the Chromodomain Y Chromosome Family of Chromodomains for Lysine-Methylated ARK(S/T) Motifs. *J. Biol. Chem.* **2008**, *283*, 19626–19635. [CrossRef] [PubMed]

19. Karczewski, K.J.; Francioli, L.C.; Tiao, G.; Cummings, B.B.; Alföldi, J.; Wang, Q.; Collins, R.L.; Laricchia, K.M.; Ganna, A.; Birnbaum, D.P.; et al. The Mutational Constraint Spectrum Quantified from Variation in 141,456 Humans. *Nature* **2020**, *581*, 434–443. [CrossRef]
20. Turner, T.N.; Wilfert, A.B.; Bakken, T.E.; Bernier, R.A.; Pepper, M.R.; Zhang, Z.; Torene, R.I.; Retterer, K.; Eichler, E.E. Sex-Based Analysis of De Novo Variants in Neurodevelopmental Disorders. *Am. J. Hum. Genet.* **2019**, *105*, 1274–1285. [CrossRef] [PubMed]

21. Jackson, D.; Malka, S.; Harding, P.; Palma, J.; Dunbar, H.; Moosajee, M. Molecular Diagnostic Challenges for Non-Retinal Developmental Eye Disorders in the United Kingdom. *Am. J. Med. Genet. C Semin. Med. Genet.* **2020**, *184*, 578–589. [CrossRef] [PubMed]

22. Damián, A.; Núñez-Moreno, G.; Jubin, C.; Tamayo, A.; De Alba, M.R.; Villaverde, C.; Fund, C.; Delépine, M.; Leduc, A.; Deleuze, J.F.; et al. Long-Read Genome Sequencing Identifies Cryptic Structural Variants in Congenital Aniridia Cases. *Hum. Genom.* **2023**, *17*, 45. [CrossRef] [PubMed]

23. Sánchez-Gaya, V.; Rada-Iglesias, A. POSTRE: A Tool to Predict the Pathological Effects of Human Structural Variants. *Nucleic Acids Res.* **2023**, *51*, e54. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.